News

Biocartis announces CE-IVD marking of its Idylla™ MSI Test

Products are for professional/laboratory use only.

 

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].

Read more

Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.

Products are for professional/laboratory use only.

On the 3rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.

Read more
Top